Filtered By:
Condition: Heart Failure
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 331 results found since Jan 2013.

Selective ß1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients
Conclusions: In the era of newer ß-blockers, selective ß1-blockers were not associated with new-onset DM. More evidence is needed to verify this relationship and the underlying mechanisms.
Source: Journal of Cardiovascular Pharmacology - January 1, 2018 Category: Cardiology Tags: Original Article Source Type: research

A New Form of This Miracle Nutrient Is 8 Times More Powerful …
CoQ10 has made the mainstream. You can find it everywhere. But the type of CoQ10 I want to tell you about has been completely ignored. That’s too bad, because this new form is 8 times better at getting into your blood and staying there. And that’s where it has its miracle-like anti-aging effects. This new form of CoQ10 may give you the opportunity to live disease-free for the rest of your life. Today, I’ll show you how this new “reduced” form of CoQ10 gives you greater power to prevent and reverse disease. You’ll also discover that it ramps up your energy levels and slows your aging process down by a remarkable...
Source: Al Sears, MD Natural Remedies - January 3, 2018 Category: Complementary Medicine Authors: Francisco Cabrera Tags: Nutrition antioxidants CoQ10 ubiquinol Source Type: news

Selective ß1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients
Conclusions: In the era of newer ß-blockers, selective ß1-blockers were not associated with new-onset DM. More evidence is needed to verify this relationship and the underlying mechanisms.
Source: Journal of Cardiovascular Pharmacology - January 1, 2018 Category: Cardiology Tags: Original Article Source Type: research

Small dense low ‐density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease
ConclusionssdLDL‐C was the most effective predictor of residual risk of future CE in stable coronary artery disease patients using statins and in high‐risk coronary artery disease patients with diabetes or hypertriglyceridemia. Geriatr Gerontol Int 2018; ••: ••–••.
Source: Geriatrics and Gerontology International - February 1, 2018 Category: Geriatrics Authors: Koshiro Sakai, Shinji Koba, Yuya Nakamura, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Yasuki Itoh, Yuji Hamazaki, Youichi Kobayashi Tags: Original Article: Epidemiology, Clinical Practice and Health Source Type: research

The Association Between Inflammatory Markers and Hypertension. A Call for Anti-Inflammatory Strategies?
Authors: García NH, Juncos LI Abstract The most important goal of antihypertensive therapy is to prevent the complications associated with hypertension (stroke, myocardial infarction, end-stage renal disease, etc). For this, secondary targets such as left ventricular hypertrophy, proteinuria, dementia, and other signs of hypertension-induced organ damage help the physician to assess risks and monitor treatment efficacy. New treatment targets may be arising, however. One such target may be endothelial dysfunction. In effect, endothelial dysfunction not only may precede the elevation of blood pressure, but may also ...
Source: The Scientific World Journal - June 7, 2018 Category: Science Tags: ScientificWorldJournal Source Type: research

Scientific expert reaction to Cochrane Review on omega-3 fatty acids
This study provides no evidence to suggest that this dietary advice should change.”Read the press releaseSee the media coverageDeclared interestsProf Tim Chico: “No conflicts.”Dr Ian Johnson: “Ian Johnson has previously held honorary academic appointments in the medical school at the University of East Anglia.”Prof Tom Sanders: “Scientific governor of British Nutrition Foundation, Honorary Director of Nutrition HEART UK.”The Science Media CentreThe Science Media Centre is an independent venture working to promote the voices, stories and views from the scientific community to the news media when science is in ...
Source: Cochrane News and Events - July 17, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Differences in management and outcomes for men and women with ST-elevation myocardial infarction.
CONCLUSION: Women with STEMI are less likely to receive invasive management, revascularisation, or preventive medication at discharge. The reasons for these persistent differences in care require investigation. PMID: 30025513 [PubMed - as supplied by publisher]
Source: Medical Journal of Australia - July 22, 2018 Category: General Medicine Tags: Med J Aust Source Type: research

Rationale and Design of the Pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study
Publication date: Available online 29 September 2018Source: American Heart JournalAuthor(s): Aruna D. Pradhan, Nina P. Paynter, Brendan M. Everett, Robert J. Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R. Hiatt, Shun Ishibashi, Wolfgang Koenig, Børge G. Nordestgaard, Jean-Charles Fruchart, Peter Libby, Paul M RidkerAbstractObservational, genetic, and experimental data indicate that triglyceride rich lipoproteins (TRLs) likely participate causally in atherothrombosis. Yet, robust clinical trial evidence that triglyceride (TG) lowering therapy reduces cardiovascular events remains elusive. The selective p...
Source: American Heart Journal - October 4, 2018 Category: Cardiology Source Type: research

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Publication date: 2–8 February 2019Source: The Lancet, Volume 393, Issue 10170Author(s): Jane Armitage, Colin Baigent, Elizabeth Barnes, D John Betteridge, Lisa Blackwell, Michael Blazing, Louise Bowman, Eugene Braunwald, Robert Byington, Christopher Cannon, Michael Clearfield, Helen Colhoun, Rory Collins, Björn Dahlöf, Kelly Davies, Barry Davis, James de Lemos, John R Downs, Paul Durrington, Jonathan EmbersonSummaryBackgroundStatin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We u...
Source: The Lancet - February 2, 2019 Category: General Medicine Source Type: research

The new GP contract: transforming primary care, transforming CVD prevention
NHS England ’s National Clinical Director for Cardiovascular Disease Prevention and the Chief Executive of the British Heart Foundation share their thoughts on the new GP contract and the positive impact that the changes could have on the outcomes and quality of life for people across the country Related items fromOnMedica Invest in GP services to improve heart failure survival Statins cut risk of strokes/heart attacks irrespective of patient ’s age Ending the postcode lottery of stroke care Hypertension: what ’s new and how might this impact practice? Know your heart health risk stats as well as your PIN number, public urged
Source: OnMedica Views - February 25, 2019 Category: Primary Care Source Type: news

Statin Use in Primary Prevention; a Simple Trial Based Approach Compared to Guideline Recommended Risk Algorithms for Selection of Eligible Patients
ConclusionThe pragmatic HOPE-3 trial approach identifies in an ethnically diverse primary prevention population individuals at intermediate risk who benefit from statin therapy using simple clinical characteristics without the need for complex, currently used risk assessment tools.
Source: Canadian Journal of Cardiology - March 19, 2019 Category: Cardiology Source Type: research

Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
CONCLUSION: Serum MDA-LDL levels on admission are a significant prognostic marker in patients with ACS who undergo successful PCI. PMID: 30898480 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - March 17, 2019 Category: Cardiology Authors: Amioka N, Miyoshi T, Otsuka H, Yamada D, Takaishi A, Ueeda M, Hirohata S, Ito H Tags: J Cardiol Source Type: research

Nrf2 as a Potential Mediator of Cardiovascular Risk in Metabolic Diseases
Conclusion Activation of the Nrf2-dependent antioxidant system plays an important role in cell defense against oxidative stress damage, whereas the insufficiency of the Nrf2 system is associated with multiple aspects of the genesis and progression of metabolic diseases, posing a great risk to the cardiovascular system (Figure 1). The systemic increase of Nrf2 activity by several activators may be beneficial in the treatment of metabolic diseases. In addition, selective upregulation of Nrf2 genes may represent a potential therapy in obesity, diabetes and atherosclerosis. Looking to the future, experimental research that el...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research

Remnant Lipoproteins Are Residual Risk Factor for Future Cardiovascular Events in Patients With Stable Coronary Artery Disease and On-Statin Low-Density Lipoprotein Cholesterol Levels < 70 mg/dL.
CONCLUSIONS: RLP-C levels are a residual risk factor for future CVEs in patients with CAD and on-statin LDL-C <70 mg/dL. PMID: 30996151 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 17, 2019 Category: Cardiology Authors: Fujihara Y, Nakamura T, Horikoshi T, Obata JE, Fujioka D, Watanabe Y, Watanabe K, Kugiyama K Tags: Circ J Source Type: research